Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUPLEXA
- Development stage
- Phase 1
- Lead developer
- Alloplex Biotherapeutics
- Modality
- Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
SUPLEXA is a personalized autologous cellular immunotherapy developed by Alloplex Biotherapeutics for the treatment of advanced cancers. It is manufactured from a patient’s own peripheral blood mononuclear cells (PBMCs), which are reprogrammed ex vivo using the proprietary ENLIST cell platform. This process activates and expands multiple immune effector cell types—including natural killer (NK) cells, natural killer T (NKT) cells, γδ T cells, and cytotoxic CD8+ and CD4+ αβ T lymphocytes—without genetic engineering. The resulting product harnesses both innate and adaptive immune mechanisms to recognize and kill tumor cells through multiple pathways. Early clinical trials have demonstrated promising safety and efficacy signals in patients with solid tumors (notably colorectal cancer and renal cell carcinoma) as wellalike hematologic malignancies such as lymphoma and chronic lymphocytic leukemia[1][2][3][4][5][6][9].
- Brand names
- SUPLEXA
- Other names
- SUPLEXA Therapeutic CellsAutologous SUPLEXASUPLEXA cell therapy
Beyond the preview
Go deeper on SUPLEXA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SUPLEXA.